These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 16750320)

  • 1. Clinicopathologic analysis of extracapsular extension in prostate cancer: should the clinical target volume be expanded posterolaterally to account for microscopic extension?
    Chao KK; Goldstein NS; Yan D; Vargas CE; Ghilezan MI; Korman HJ; Kernen KM; Hollander JB; Gonzalez JA; Martinez AA; Vicini FA; Kestin LL
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):999-1007. PubMed ID: 16750320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment prostate-specific antigen and Gleason score predict the risk of extracapsular extension and the risk of failure following radiotherapy in patients with clinically localized prostate cancer.
    Roach M; Chen A; Song J; Diaz A; Presti J; Carroll P
    Semin Urol Oncol; 2000 May; 18(2):108-14. PubMed ID: 10875450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Side-specific factors associated with extracapsular extension and seminal vesicular invasion in men undergoing open radical retropubic prostatectomy.
    Sankin A; Tareen B; Lepor H
    Prostate Cancer Prostatic Dis; 2009; 12(2):204-8. PubMed ID: 19238170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative and intraoperative risk factors for side-specific positive surgical margins in laparoscopic radical prostatectomy for prostate cancer.
    Secin FP; Serio A; Bianco FJ; Karanikolas NT; Kuroiwa K; Vickers A; Touijer K; Guillonneau B
    Eur Urol; 2007 Mar; 51(3):764-71. PubMed ID: 17098356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of extracapsular extension of prostate cancer based on systematic core biopsies.
    Tarján M; Tot T
    Scand J Urol Nephrol; 2006; 40(6):459-64. PubMed ID: 17130097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediagnostic prostate-specific antigen velocity and probability of detecting high-grade prostate cancer.
    Krejcarek SC; Chen MH; Renshaw AA; Loffredo M; Sussman B; D'Amico AV
    Urology; 2007 Mar; 69(3):515-9. PubMed ID: 17382156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The radial distance of extraprostatic extension of prostate carcinoma: implications for prostate brachytherapy.
    Davis BJ; Pisansky TM; Wilson TM; Rothenberg HJ; Pacelli A; Hillman DW; Sargent DJ; Bostwick DG
    Cancer; 1999 Jun; 85(12):2630-7. PubMed ID: 10375112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features.
    Dattoli M; Wallner K; True L; Cash J; Sorace R
    Cancer; 2007 Aug; 110(3):551-5. PubMed ID: 17577217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium.
    Chun FK; Briganti A; Gallina A; Hutterer GC; Shariat SF; Antebie E; Walz J; Roehrborn CG; Salonia A; Rigatti P; Saad F; Huland H; Montorsi F; Graefen M; Karakiewicz PI
    Eur Urol; 2007 Oct; 52(4):1067-74. PubMed ID: 17383807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer.
    Ohori M; Kattan MW; Koh H; Maru N; Slawin KM; Shariat S; Muramoto M; Reuter VE; Wheeler TM; Scardino PT
    J Urol; 2004 May; 171(5):1844-9; discussion 1849. PubMed ID: 15076291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
    Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
    Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of prostate volume on tumor grade in patients undergoing radical prostatectomy in the era of extended prostatic biopsies.
    Kassouf W; Nakanishi H; Ochiai A; Babaian KN; Troncoso P; Babaian RJ
    J Urol; 2007 Jul; 178(1):111-4. PubMed ID: 17499289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.
    Whitman EJ; Groskopf J; Ali A; Chen Y; Blase A; Furusato B; Petrovics G; Ibrahim M; Elsamanoudi S; Cullen J; Sesterhenn IA; Brassell S; Rittenhouse H; Srivastava S; McLeod DG
    J Urol; 2008 Nov; 180(5):1975-8; discussion 1978-9. PubMed ID: 18801539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
    Bastian PJ; Gonzalgo ML; Aronson WJ; Terris MK; Kane CJ; Amling CL; Presti JC; Mangold LA; Humphreys E; Epstein JI; Partin AW; Freedland SJ
    Cancer; 2006 Sep; 107(6):1265-72. PubMed ID: 16900523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathological features of Gleason score 6 prostate cancers in the low and intermediate range of prostate-specific antigen level: is there a difference?
    Pelzer AE; Colleselli D; Bektic J; Steiner E; Ramoner R; Mitterberger M; Schwentner C; Schaefer G; Ongarello S; Bartsch G; Horninger W
    BJU Int; 2008 Apr; 101(7):822-5. PubMed ID: 18261154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer volume at biopsy predicts clinically significant upgrading.
    Dong F; Jones JS; Stephenson AJ; Magi-Galluzzi C; Reuther AM; Klein EA
    J Urol; 2008 Mar; 179(3):896-900; discussion 900. PubMed ID: 18207180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should we replace the Gleason score with the amount of high-grade prostate cancer?
    Vis AN; Roemeling S; Kranse R; Schröder FH; van der Kwast TH
    Eur Urol; 2007 Apr; 51(4):931-9. PubMed ID: 16935413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of radial distance of extraprostatic extension from pretherapy factors.
    Schwartz DJ; Sengupta S; Hillman DW; Sargent DJ; Cheville JC; Wilson TM; Mynderse LA; Choo R; Davis BJ
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):411-8. PubMed ID: 17869661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T1c prostate cancer detection rate and pathologic characteristics: comparison between patients with serum prostate-specific antigen range of 3.0 to 4.0 ng/mL and 4.1 to 10.0 ng/mL in Korean population.
    Park HK; Hong SK; Byun SS; Lee SE
    Urology; 2006 Jul; 68(1):85-8. PubMed ID: 16806412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radial distance of extraprostatic extension measured by ocular micrometer is an independent predictor of prostate-specific antigen recurrence: A new proposal for the substaging of pT3a prostate cancer.
    Sung MT; Lin H; Koch MO; Davidson DD; Cheng L
    Am J Surg Pathol; 2007 Feb; 31(2):311-8. PubMed ID: 17255778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.